Every 10-Q that IDEX Corporation (IEX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IEX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IEX filings page.
IDEX Corporation reported higher Q2 2026 results, with net sales of $920.6 million up 6% and net income attributable to IDEX of $143.4 million. Diluted EPS rose to $1.93, and gross margin expanded to 46.3%, helped by stronger Health & Science Technologies volumes and positive price/cost.
A U.S. Supreme Court ruling on the International Emergency Economic Powers Act led to $22.0 million of tariff refunds recorded in Cost of sales and $14.7 million of related customer rebates in Net sales, providing a net EPS benefit of $0.08. For the first half, net sales were $1,807.5 million and diluted EPS $3.54; free cash flow, a non-GAAP measure, was $263.0 million. Cash and cash equivalents totaled $621.3 million against total borrowings of $1,866.9 million, and the company returned capital through $151.3 million of share repurchases and $106.7 million of dividends while maintaining significant unused revolver capacity.
IDEX Corporation reported solid first-quarter 2026 growth. Net sales rose to $886.9 million from $814.3 million, helped by 5% organic growth, favorable currency and contributions from acquisitions. Net income attributable to IDEX increased to $120.0 million from $95.5 million, with diluted EPS up to $1.61 from $1.26.
Adjusted diluted EPS reached $2.00, up from $1.75, reflecting higher volumes in advantaged markets such as data centers, semiconductors, and space and defense within Health & Science Technologies. Gross margin eased slightly to 44.9% from 45.3% as unfavorable mix and price/cost pressure offset productivity gains and volume leverage.
IDEX generated $103.7 million of operating cash flow and $86.0 million of free cash flow, while investing $17.7 million in capital expenditures. The company returned cash to shareholders through $75.6 million of share repurchases and $52.8 million of dividends. The balance sheet showed $586.2 million of cash, total borrowings of $1.88 billion, and ample liquidity with $517.2 million available under its $800 million revolving facility.
IDEX Corporation (IEX) reported higher quarterly results. For the three months ended September 30, 2025, net sales were $878.7 million, up from $798.2 million, with operating income of $185.8 million versus $168.0 million. Diluted EPS was $1.70 compared with $1.57 a year ago.
Nine-month results were mixed: net sales rose to $2,558.4 million from $2,405.9 million, while net income attributable to IDEX was $354.9 million versus $381.8 million, and diluted EPS was $4.70 versus $5.02. Operating cash flow reached $470.9 million. The company repurchased $175.0 million of common stock year to date and declared a quarterly dividend of $0.71 per share.
Health & Science Technologies led growth, with Q3 revenue of $380.1 million (from $309.9 million), aided by acquisitions. IDEX completed the acquisition of Micro‑LAM for total consideration of $81.9 million and ended the quarter with cash and cash equivalents of $593.8 million and total borrowings of $1,911.8 million, including $310.6 million drawn on its revolving facility.